Table 1: Summary of the impact of binding affinity changes in the CD8-Hla Class I interaction, the potential immunotherapy agonist and antagonist drug actions and their impact on immunological function.
|Interaction||Binding Affinity (KD)||CD8-HLA Class I Drug Action||Immunological Outcome|
|CD8-HLA Class I Wild Type||145 µM||Nil||Normal T Cell Activity|
|CD8-HLA Class I (Q115E)||85 µM||Weak Agonist||Enhanced Activity Cognate Specificity Enhanced T Cell Specific Killing|
|CD8-HLA-A2/Kb||10 µM||Strong Agonist||Loss of Cognate HLA/Peptide Specificity Targets Killed by all T Cells|
|CD8 -HLA Class I (D227K/T228A)||> 10,000 µM||Antagonist||Loss of T Cell Activity|